Glen Eagle Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Glen Eagle Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.68M	Sell	20,985 -311	-1%	-$38.8K	0.38%	49
2025 Q4	$2.6M	Buy	21,296 +931	+5%	+$107K	0.35%	57
2025 Q3	$2.04M	Sell	20,365 -5	-0%	-$450	0.28%	66
2025 Q2	$1.69M	Sell	20,370 -515	-2%	-$41.1K	0.26%	72
2025 Q1	$1.69M	Buy	20,885 +55	+0.3%	+$4.92K	0.28%	65
2024 Q4	$1.88M	Buy	20,830 +1,654	+9%	+$160K	0.31%	63
2024 Q3	$1.89M	Sell	19,176 -347	-2%	-$34.1K	0.32%	64
2024 Q2	$1.81M	Buy	19,523 +120	+0.6%	+$10.8K	0.33%	62
2024 Q1	$1.84M	Buy	19,403 +340	+2%	+$31.5K	0.35%	61
2023 Q4	$1.7M	Buy	19,063 +680	+4%	+$50.5K	0.35%	58
2023 Q3	$1.34M	Buy	18,383 +118	+0.6%	+$9.43K	0.31%	69
2023 Q2	$1.52M	Buy	18,265 +2,417	+15%	+$202K	0.35%	62
2023 Q1	$1.21M	Sell	15,848 -243	-2%	-$20.2K	0.3%	71
2022 Q4	$1.34M	Sell	16,091 -1,275	-7%	-$103K	0.36%	59
2022 Q3	$1.38M	Sell	17,366 -344	-2%	-$29K	0.4%	57
2022 Q2	$1.32M	Sell	17,710 -1,115	-6%	-$83.7K	0.36%	62
2022 Q1	$1.69M	Buy	18,825 +55	+0.3%	+$5.08K	0.44%	52
2021 Q4	$2.1M	Buy	18,770 +226	+1%	+$27.3K	0.55%	42
2021 Q3	$2.33M	Buy	18,544 +433	+2%	+$55.8K	0.67%	35
2021 Q2	$2.45M	Buy	18,111 +395	+2%	+$51.9K	0.76%	30
2021 Q1	$2.4M	Buy	17,716 +495	+3%	+$74.1K	0.84%	27
2020 Q4	$2.42M	Buy	17,221 +45	+0.3%	+$5.76K	0.95%	21
2020 Q3	$1.91M	Buy	17,176 +180	+1%	+$20.2K	0.86%	28
2020 Q2	$1.9M	Buy	16,996 +320	+2%	+$31.5K	0.98%	22
2020 Q1	$1.29M	Sell	16,676 -145	-0.9%	-$12.8K	0.91%	28
2019 Q4	$1.6M	Buy	16,821 +1,862	+12%	+$161K	0.85%	29
2019 Q3	$1.14M	Sell	14,959 -921	-6%	-$76.5K	0.75%	31
2019 Q2	$1.39M	Buy	15,880 +252	+2%	+$21.5K	0.95%	23
2019 Q1	$1.41M	Sell	15,628 -125	-0.8%	-$10.6K	1.03%	20
2018 Q4	$1.1M	Sell	15,753 -1,385	-8%	-$112K	0.93%	25
2018 Q3	$1.64M	Buy	17,138 +1,595	+10%	+$155K	1.17%	20
2018 Q2	$1.48M	Buy	15,543 +875	+6%	+$80.4K	1.16%	19
2018 Q1	$1.29M	Buy	14,668 +2,031	+16%	+$185K	1.06%	22
2017 Q4	$1.07M	Buy	12,637 +2,161	+21%	+$181K	0.93%	21
2017 Q3	$907K	Sell	10,476 -6,584	-39%	-$528K	0.85%	28
2017 Q2	$1.33M	Buy	17,060 +670	+4%	+$47.5K	1.06%	17
2017 Q1	$1.14M	Buy	16,390 +770	+5%	+$51.7K	0.98%	19
2016 Q4	$925K	Buy	+15,620	New	+$964K	0.83%	23

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Glen Eagle Advisors's XBI Position: Q1 2026 in Review

Glen Eagle Advisors reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.5% in Q1 2026, selling an estimated $38.8K and leaving 20,985 shares worth $2.68M. The position accounts for 0.38% of the portfolio, ranked #49.

Glen Eagle Advisors first reported a position in XBI in Q4 2016 and has held it in 38 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Glen Eagle Advisors held 20,985 shares of State Street SPDR S&P Biotech ETF worth $2.68M as of Q1 2026.
Glen Eagle Advisors sold 311 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $38.8K.
State Street SPDR S&P Biotech ETF made up 0.38% of Glen Eagle Advisors's portfolio in Q1 2026, its #49 holding.
Glen Eagle Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 38 quarters since.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.